Jane Emerson, MD
Physical Medicine & Rehabilitation · Columbia, MONPI 1164479531
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Ipsen Biopharmaceuticals, Inc accounts for 76.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $19,689 and has fallen 51.6% since, to $9,531 in 2025. Among physical medicine & rehabilitation clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $591.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$34K
- Sarepta Therapeutics, Inc.$10K
- AbbVie$206
- Medtronic$187
- Piramal Critical Care$145
- Biogen$113
- plus $233 from 5 others
Across 20 payments — averaging $3140.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$55K
- Novartis$7K
- Merz North America, Inc.$1K
What the payments were for
- Consulting fees$11,26525%
- Speaking & faculty fees$24,70856%
- Travel & lodging$5,06111%
- Food & beverage$3,2927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 36 | $33,741 |
| Sarepta Therapeutics, Inc. | 18 | $9,699 |
| AbbVie | 2 | $206 |
| Medtronic(2 entities) | 2 | $187 |
| Piramal Critical Care | 1 | $145 |
| Biogen | 6 | $113 |
| NS Pharma, Inc. | 6 | $111 |
| Merz Pharmaceuticals, LLC | 1 | $58 |
| Saol Therapeutics Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Rochester Medical Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$33,404
- Elevidys$8,945
- SYNCHROMED$166
- GABLOFEN$145
- GABLOFEN 1 mL in 1 SYRINGE, GLASS$145
- BOTOX$135
How this compares
$44,326 in reported general payments places this provider in the 95th percentile of 182 physical medicine & rehabilitation providers in Missouri.
See all physical medicine & rehabilitation providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 13 | $178 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Columbia
- Joseph BurrisColumbia$75K
- Reza FaridColumbia$37K
- Vovanti JonesColumbia$9K
- Rachael BrashearsColumbia$7K
- Hannah FarmerColumbia$4K
- John AlmColumbia$3K
- Nicholas MadafferColumbia$3K
- Mark DrymalskiColumbia$992
- Megan ClarkColumbia$564
- Kevin ThomasColumbia$399
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.